Adalimumab: in Crohn's disease

Area of Science:

• Gastroenterology
• Immunology
• Pharmacology

Background:

• Crohn's disease is a chronic inflammatory bowel disease requiring effective therapeutic options.
• Tumor necrosis factor (TNF) inhibitors are a key treatment modality for moderate to severe Crohn's disease.

Purpose of the Study:

• To evaluate the efficacy and safety of adalimumab, a human monoclonal antibody targeting TNF, in patients with moderate to severe Crohn's disease.

Main Methods:

• Four pivotal randomized, double-blind trials (CLASSIC-I, GAIN, CHARM, CLASSIC-II) involving over 1400 patients were conducted.
• Studies assessed adalimumab for induction of remission, maintenance of remission, corticosteroid-free remission, fistula closure, and overall tolerability.

Main Results:

• Adalimumab demonstrated significantly greater efficacy than placebo for induction of remission in both anti-TNF-naïve patients and those with loss of response or intolerance to infliximab.
• Maintenance therapy with adalimumab (40 mg weekly or every other week) significantly improved remission rates, corticosteroid-free remission, and fistula closure compared to placebo.
• Adalimumab recipients were more likely to maintain remission over one year compared to placebo recipients.

Conclusions:

• Adalimumab is a clinically effective and well-tolerated treatment for moderate to severe Crohn's disease.
• The drug provides significant benefits for both induction and maintenance of remission, including in patients with prior anti-TNF therapy exposure.
• Adalimumab offers a valuable therapeutic option for managing Crohn's disease, improving patient outcomes and quality of life.